Xiao-Liang Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiao-Liang Liu has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Han Zhu
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, People’s Republic of China
2 shared publications - Jianmin Yang
Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai 200433, China
2 shared publications - Kehong Bi
18Department of Hematology, The First Affiliated Hospital of Shandong First Medical University, Jinan, China
2 shared publications - Ming Jiang
Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
2 shared publications - Shunqing Wang
Department of Hematology, Guangzhou First People’s Hospital, Institute of Blood Transfusion and Hematology, Guangzhou Medical University, Guangzhou, China
2 shared publications - Song Wang
Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
2 shared publications
Latest Publications
- Open Access
- 28 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 4951
A Prediction Model for Early Recurrence after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with CMML: A Nationwide Representative Multicenter Study
Introduction: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell malignancy. Some patients experience prolonged remission after aggressive chemotherapy, but the only current therapy with proven curative potential is allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, not all CMML patients benefit from allo-HSCT, and many experience relapse. Relapse is the leading cause of treatment failure for CMML treated with allo-HSCT, and treatment options for patients relapsing after allo-HSCT are limited. This study conducted a nationwide multicenter real-world study to identify risk factors and develop a novel prediction model for early recurrence in CMML patient posttransplantation. Clinicians can improve the survival of CMML patients with a high risk of early recurrence by intervening as early as possible. Methods: Patients ≥18 years old with CMML treated with allo-HSCT for the first time between 2005 and 2022 were included in this nationwide, multicenter, real-world study. Twenty-seven medical centers participated in this analysis, including the derivation cohort from 26 centers and the validation cohort from another center. Information collected included demographic and clinical characteristics, previous treatments and responses, and allo-HSCT treatment details. We first calculated the univariable association of each variable with 1-year relapse in the derivation cohort. Second, the variables with p values less than 0.1 in the univariate analysis were further included as candidate predictors in the multivariate analysis using a backward stepwise logistic regression model. The variables that remained in the final model based on the outcomes of the multivariate analysis in the derivation cohort were identified as independent prognostic factors. A scoring system to predict early recurrence after allo-HSCT was also established, and scores were assigned to the prognostic factors based on the regression coefficient. Results: Using multivariable logistic regression methods with stepwise variable selection, two highly significant independent prognostic factors for the early recurrence of CMML posttransplantation were identified: bone marrow blast cell count at diagnosis (p=0.026; odds ratio [OR], 1.149; 95% confidence interval [CI], 1.02-1.30), and leukocyte count pretransplantation (p=0.005; odds ratio [OR], 1.212; 95% confidence interval [CI], 1.06-1.39). A risk grading model was constructed according to the regression coefficients. Bone marrow blast cell count 0-5% is 0 point, 5%-10% is 1 point; 10-20% is 2 points, and >20% is 3 points. Leukocyte count 0-10×10 9/L is 0 point, 10-20×10 9/L is 2 points, and >20 ×10 9/L is 4 points. The points scored for each of these two factors were added to yield the overall risk score, which ranged from zero to seven. Patients were stratified into a low-risk group (0-1 point), a intermediate-risk group (2-3 points) and a high-risk group (4-7 points). The validated internal c-statistic was 0.790 (95% CI, 0.657-0.923), and the external c-statistic was 0.710 (95% CI, 0.580-0.840). The early recurrence rates of the derivation cohort in the low-risk, intermediate-risk, and high-risk groups were 5.9%, 17.9% and 31.8% (pConclusion: CMML patients who relapse after allo-HSCT have a poor prognosis. An integrated prediction model based on clinical biomarkers was developed and externally validated, and this is the first straightforward scoring model that incorporates clinical and laboratory risk factors to evaluate the early recurrence of CMML patients after receiving allo-HSCT. This model can be effectively utilized to help improve the survival and prognosis of CMML patients by accelerating the early identification of patients at a high risk of relapse and contributing to the appropriate implementation of urgent medical support. No relevant conflicts of interest to declare.
- 28 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 4951
Open AccessA Prediction Model for Early Recurrence after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with CMML: A Nationwide Representative Multicenter Study
Introduction: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell malignancy. Some patients experience prolonged remission after aggressive chemotherapy, but the only current therapy with proven curative potential is allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, not all CMML patients benefit from allo-HSCT, and many experience relapse. Relapse is the leading cause of treatment failure for CMML treated with allo-HSCT, and treatment options for patients relapsing after allo-HSCT are limited. This study conducted a nationwide multicenter real-world study to identify risk factors and develop a novel prediction model for early recurrence in CMML patient posttransplantation. Clinicians can improve the survival of CMML patients with a high risk of early recurrence by intervening as early as possible. Methods: Patients ≥18 years old with CMML treated with allo-HSCT for the first time between 2005 and 2022 were included in this nationwide, multicenter, real-world study. Twenty-seven medical centers participated in this analysis, including the derivation cohort from 26 centers and the validation cohort from another center. Information collected included demographic and clinical characteristics, previous treatments and responses, and allo-HSCT treatment details. We first calculated the univariable association of each variable with 1-year relapse in the derivation cohort. Second, the variables with p values less than 0.1 in the univariate analysis were further included as candidate predictors in the multivariate analysis using a backward stepwise logistic regression model. The variables that remained in the final model based on the outcomes of the multivariate analysis in the derivation cohort were identified as independent prognostic factors. A scoring system to predict early recurrence after allo-HSCT was also established, and scores were assigned to the prognostic factors based on the regression coefficient. Results: Using multivariable logistic regression methods with stepwise variable selection, two highly significant independent prognostic factors for the early recurrence of CMML posttransplantation were identified: bone marrow blast cell count at diagnosis (p=0.026; odds ratio [OR], 1.149; 95% confidence interval [CI], 1.02-1.30), and leukocyte count pretransplantation (p=0.005; odds ratio [OR], 1.212; 95% confidence interval [CI], 1.06-1.39). A risk grading model was constructed according to the regression coefficients. Bone marrow blast cell count 0-5% is 0 point, 5%-10% is 1 point; 10-20% is 2 points, and >20% is 3 points. Leukocyte count 0-10×10 9/L is 0 point, 10-20×10 9/L is 2 points, and >20 ×10 9/L is 4 points. The points scored for each of these two factors were added to yield the overall risk score, which ranged from zero to seven. Patients were stratified into a low-risk group (0-1 point), a intermediate-risk group (2-3 points) and a high-risk group (4-7 points). The validated internal c-statistic was 0.790 (95% CI, 0.657-0.923), and the external c-statistic was 0.710 (95% CI, 0.580-0.840). The early recurrence rates of the derivation cohort in the low-risk, intermediate-risk, and high-risk groups were 5.9%, 17.9% and 31.8% (pConclusion: CMML patients who relapse after allo-HSCT have a poor prognosis. An integrated prediction model based on clinical biomarkers was developed and externally validated, and this is the first straightforward scoring model that incorporates clinical and laboratory risk factors to evaluate the early recurrence of CMML patients after receiving allo-HSCT. This model can be effectively utilized to help improve the survival and prognosis of CMML patients by accelerating the early identification of patients at a high risk of relapse and contributing to the appropriate implementation of urgent medical support. No relevant conflicts of interest to declare.
- Open Access
- 8 August 2023
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 7 (S3) , e1182717
P1277: IMPACT OF A NOVEL PROGNOSTIC MODEL ON ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES IN PATIENTS WITH CMML
- 8 August 2023
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 7 (S3) , e1182717
Open AccessP1277: IMPACT OF A NOVEL PROGNOSTIC MODEL ON ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES IN PATIENTS WITH CMML
- Open Access
- 1 April 2022
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 15, 3625-3637
Development and Validation of a Prediction Model for Predicting the Prognosis of Postoperative Patients with Hepatocellular Carcinoma
Purpose: The aims of this study were to identify the prognosis-related risk factors for HCC patients after surgery and to develop a predictive model by analysing the medical records of 152 HCC patients in our hospital. Patients and Methods: Univariate Cox regression analysis was applied to identify potential risk factors for HCC patients after surgery and to determine independent prognosis-related risk factors by multivariate analysis. Subsequently, a nomogram model was developed based on all independent factors and was validated by a validation set. Calibration and receiver operating characteristic curves were employed to evaluate the accuracy of the model. Finally, decision curve analyses were used to assess its clinical utility. Results: The univariate Cox regression analysis indicated that the patient’s age, sex, grade, different AJCC TNM stages, vascular invasion, lymphatic infiltration, and tumour size were potential prognostic-related risk factors for HCC patients (p < 0.2), and the findings of multivariate analysis revealed that grade, different AJCC TNM stages, vascular invasion, and lymphatic infiltration were independent prognostic-related risk factors for HCC patients (p < 0.05). Subsequently, we constructed a prognosis-related prediction model based on all independent prognostic predictors and validated it with internal and external validation sets. The validation results indicated that the prediction model showed good accuracy (AUC = 0.81, 0.728) and consistency. More importantly, decision curve analysis illustrated that the nomogram model is a practical tool for predicting prognosis. Conclusion: This study found that grade, different AJCC TNM stages, vascular invasion, and lymphatic infiltration were independent prognosis-related predictors for HCC patients after surgery, and a nomogram model built on these predictors exhibited great accuracy and clinical usefulness.
- 1 April 2022
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 15, 3625-3637
Open AccessDevelopment and Validation of a Prediction Model for Predicting the Prognosis of Postoperative Patients with Hepatocellular Carcinoma
Purpose: The aims of this study were to identify the prognosis-related risk factors for HCC patients after surgery and to develop a predictive model by analysing the medical records of 152 HCC patients in our hospital. Patients and Methods: Univariate Cox regression analysis was applied to identify potential risk factors for HCC patients after surgery and to determine independent prognosis-related risk factors by multivariate analysis. Subsequently, a nomogram model was developed based on all independent factors and was validated by a validation set. Calibration and receiver operating characteristic curves were employed to evaluate the accuracy of the model. Finally, decision curve analyses were used to assess its clinical utility. Results: The univariate Cox regression analysis indicated that the patient’s age, sex, grade, different AJCC TNM stages, vascular invasion, lymphatic infiltration, and tumour size were potential prognostic-related risk factors for HCC patients (p < 0.2), and the findings of multivariate analysis revealed that grade, different AJCC TNM stages, vascular invasion, and lymphatic infiltration were independent prognostic-related risk factors for HCC patients (p < 0.05). Subsequently, we constructed a prognosis-related prediction model based on all independent prognostic predictors and validated it with internal and external validation sets. The validation results indicated that the prediction model showed good accuracy (AUC = 0.81, 0.728) and consistency. More importantly, decision curve analysis illustrated that the nomogram model is a practical tool for predicting prognosis. Conclusion: This study found that grade, different AJCC TNM stages, vascular invasion, and lymphatic infiltration were independent prognosis-related predictors for HCC patients after surgery, and a nomogram model built on these predictors exhibited great accuracy and clinical usefulness.
- 1 January 2022
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 28 (3) , 216-224
Anlotinib-Induced Hypertension: Current Concepts and Future Prospects
Background: Anlotinib is a new tyrosine kinase inhibitor developed in China that targets the receptors for vascular endothelial growth factor, platelet-derived growth factor, fibroblast growth factor, and stem cell factor. Therefore, anlotinib inhibits tumor angiogenesis, representing a new therapeutic alternative for lung cancer. Hypertension is one of its most common adverse effects, leading to discontinuation of the drug and limited clinical usefulness. Objective: The present review aims to summarize the evidence on the prevalence, physiopathology, and management of anlotinib-induced hypertension, as well as its effect on the cancer prognosis. Method: Searches in Medline, Cochrane Central Library, and Embase were performed using the following terms: anlotinib, adverse effect, hypertension, clinical trial, vascular endothelial growth factor, and anti-angiogenic drugs. Citations were also identified by checking the reference sections of selected papers. Results: Except for a phase I clinical trial with a small sample size (n = 6), almost all the clinical trials on anlotinib have reported the development of anlotinib-induced hypertension. In these trials, the incidence of hypertension ranged from 13% to 67.7%, and that of grade 3/4 hypertension ranged from 4.8% to 16%. Alterations in nitric oxide, endothelin-1, microvascular rarefaction, selective vasoconstrictions, and renal injury have been cited as potential mechanisms leading to anlotinib-induced hypertension. When needed, treatment may include general hygienic measures and pharmacotherapy in some cases. Conclusions: To effectively manage anlotinib-induced hypertension, early prevention, a reasonable dosage regimen, and appropriate treatment are critical to effectively manage anlotinib-induced hypertension. Additionally, anlotinib-induced hypertension may be considered a marker for predicting efficacy.
- 1 January 2022
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 28 (3) , 216-224
Anlotinib-Induced Hypertension: Current Concepts and Future Prospects
Background: Anlotinib is a new tyrosine kinase inhibitor developed in China that targets the receptors for vascular endothelial growth factor, platelet-derived growth factor, fibroblast growth factor, and stem cell factor. Therefore, anlotinib inhibits tumor angiogenesis, representing a new therapeutic alternative for lung cancer. Hypertension is one of its most common adverse effects, leading to discontinuation of the drug and limited clinical usefulness. Objective: The present review aims to summarize the evidence on the prevalence, physiopathology, and management of anlotinib-induced hypertension, as well as its effect on the cancer prognosis. Method: Searches in Medline, Cochrane Central Library, and Embase were performed using the following terms: anlotinib, adverse effect, hypertension, clinical trial, vascular endothelial growth factor, and anti-angiogenic drugs. Citations were also identified by checking the reference sections of selected papers. Results: Except for a phase I clinical trial with a small sample size (n = 6), almost all the clinical trials on anlotinib have reported the development of anlotinib-induced hypertension. In these trials, the incidence of hypertension ranged from 13% to 67.7%, and that of grade 3/4 hypertension ranged from 4.8% to 16%. Alterations in nitric oxide, endothelin-1, microvascular rarefaction, selective vasoconstrictions, and renal injury have been cited as potential mechanisms leading to anlotinib-induced hypertension. When needed, treatment may include general hygienic measures and pharmacotherapy in some cases. Conclusions: To effectively manage anlotinib-induced hypertension, early prevention, a reasonable dosage regimen, and appropriate treatment are critical to effectively manage anlotinib-induced hypertension. Additionally, anlotinib-induced hypertension may be considered a marker for predicting efficacy.
- Open Access
- 16 July 2021
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 9 (20) , 5588-5593
Can kissing cause paraquat poisoning: A case report and review of literature
Paraquat is an effective, broad-spectrum, highly toxic quaternary ammonium herbicide. Paraquat poisoning has been reported frequently in recent years. It has severe lung, kidney, liver, and nervous system toxicity, and there is currently no specific antidote. Paraquat poisoning may follow ingestion, inhalation, and skin contact. There have been no previous reports of paraquat poisoning that resulted from kissing. This rare case provides a new reference for the prevention of paraquat poisoning. A 27-year-old man came to the emergency department complaining that he had come into contact with paraquat by kissing his girlfriend, who had taken 80-120 mL 20% paraquat. After admission, his lung computed tomography (CT) showed increased lung markings. Redness and a burning sensation developed on his tongue, which progressed to painful erosions and coalescent ulcers. The final diagnosis was mild paraquat poisoning. Anti-inflammatory, antioxidant, and symptomatic treatment were initiated and continued for 7 d. Dyspnea did not occur, subsequent lung CT showed no significant changes, and the tongue pain was slightly improved. One month after discharge, the tongue injury was resolved. This case indicated that the tongue and lung tissues are particularly vulnerable to paraquat toxicity, even after a limited exposure.
- 16 July 2021
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 9 (20) , 5588-5593
Open AccessCan kissing cause paraquat poisoning: A case report and review of literature
Paraquat is an effective, broad-spectrum, highly toxic quaternary ammonium herbicide. Paraquat poisoning has been reported frequently in recent years. It has severe lung, kidney, liver, and nervous system toxicity, and there is currently no specific antidote. Paraquat poisoning may follow ingestion, inhalation, and skin contact. There have been no previous reports of paraquat poisoning that resulted from kissing. This rare case provides a new reference for the prevention of paraquat poisoning. A 27-year-old man came to the emergency department complaining that he had come into contact with paraquat by kissing his girlfriend, who had taken 80-120 mL 20% paraquat. After admission, his lung computed tomography (CT) showed increased lung markings. Redness and a burning sensation developed on his tongue, which progressed to painful erosions and coalescent ulcers. The final diagnosis was mild paraquat poisoning. Anti-inflammatory, antioxidant, and symptomatic treatment were initiated and continued for 7 d. Dyspnea did not occur, subsequent lung CT showed no significant changes, and the tongue pain was slightly improved. One month after discharge, the tongue injury was resolved. This case indicated that the tongue and lung tissues are particularly vulnerable to paraquat toxicity, even after a limited exposure.
- 1 December 2013
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 41, A114
470
Introduction: Epinephrine (Epi) is recommended in cardiopulmonary resuscitation (CPR). Vasopressin (Vaso) has been studied for use in CPR as an alternative. Methods: The rat model of cardiac arrest (CA) after asphyxia was used in the current study. 200 rats were divided into 5 groups randomly (n=40 rats in each group) JOURNAL/ccme/04.02/00003246-201312001-00432/math_432MM1/v/2017-07-20T221830Z/r/image-tiff Sham-operated group: no asphyxia and no CPR, only for endotracheal intubation. Control group: after CA, CPR was performed immediately and 1 ml of saline was administered. Epi group: CPR was implemented after CA and 1 ml of Epi (0.2mg/kg) was administered. Vaso group: after CA, CPR was carried out and 1 ml of Vaso (0.8U/Kg) was injected. Combination group: CPR was performed after CA. 1 ml of Epi (0.2mg/kg) and 1 ml of Vaso (0.8U/Kg) were administered. The rats in control group exhibited the lowest survival rate and therefore were abandoned in the following experiment. The rats survived from other groups were killed in 1, 3, 6 and 12 hours after CPR, respectively, and the brains were taken out. We tested the expression of Caspase-3 in rat’s hippocampus by immunohistochemistry. The restoration of spontaneous circulation (ROSC) rate was recorded and the pathological changes of the brains were observed in each group. Results: Compared to Epi group, the expressions of Caspase-3 in Vaso group and combination group were lower (P0.05). HE staining demonstrated there was no difference in morphology changes among Epi, Vaso and combination group under light microscope. Compared to Sham-operated group, the edema of neurons in Hippocampus was seen in the other three groups. The damage of Mitochondria was more serious in Epi group than in Vaso and combination group under electron microscope. No difference of Mitochondria damage was seen between Vaso and combination group. Conclusions: Vaso can reduce the expression of Caspase-3 in Hippocampus of rats with CA after asphyxia and alleviate the ischemia reperfusion injury during CPR.
- 1 December 2013
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 41, A114
470
Introduction: Epinephrine (Epi) is recommended in cardiopulmonary resuscitation (CPR). Vasopressin (Vaso) has been studied for use in CPR as an alternative. Methods: The rat model of cardiac arrest (CA) after asphyxia was used in the current study. 200 rats were divided into 5 groups randomly (n=40 rats in each group) JOURNAL/ccme/04.02/00003246-201312001-00432/math_432MM1/v/2017-07-20T221830Z/r/image-tiff Sham-operated group: no asphyxia and no CPR, only for endotracheal intubation. Control group: after CA, CPR was performed immediately and 1 ml of saline was administered. Epi group: CPR was implemented after CA and 1 ml of Epi (0.2mg/kg) was administered. Vaso group: after CA, CPR was carried out and 1 ml of Vaso (0.8U/Kg) was injected. Combination group: CPR was performed after CA. 1 ml of Epi (0.2mg/kg) and 1 ml of Vaso (0.8U/Kg) were administered. The rats in control group exhibited the lowest survival rate and therefore were abandoned in the following experiment. The rats survived from other groups were killed in 1, 3, 6 and 12 hours after CPR, respectively, and the brains were taken out. We tested the expression of Caspase-3 in rat’s hippocampus by immunohistochemistry. The restoration of spontaneous circulation (ROSC) rate was recorded and the pathological changes of the brains were observed in each group. Results: Compared to Epi group, the expressions of Caspase-3 in Vaso group and combination group were lower (P0.05). HE staining demonstrated there was no difference in morphology changes among Epi, Vaso and combination group under light microscope. Compared to Sham-operated group, the edema of neurons in Hippocampus was seen in the other three groups. The damage of Mitochondria was more serious in Epi group than in Vaso and combination group under electron microscope. No difference of Mitochondria damage was seen between Vaso and combination group. Conclusions: Vaso can reduce the expression of Caspase-3 in Hippocampus of rats with CA after asphyxia and alleviate the ischemia reperfusion injury during CPR.
- 1 December 2012
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 40, 1-328
1181